Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide in MDS with del(5q)
NCT00065156Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Jun 2003
- Primary completion
- Aug 2008
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of lenalidomide in myelodysplastic syndrome (MDS), sponsored by Celgene Corporation. Started Jun 2003; status: completed.
02
Drugs
lenalidomide
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00065156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00065156.